Keywords: Anchor Thera, Johnson & Johnson, Ortho-McNeil Janssen, Oncology, Metabolic disease, Pepducin technology
Anchor Thera to sell rights to cancer, metabolic disease drug candidates to Johnson & Johnson unit for $480 million
Article | 10 September 2010
Massachusetts, USA-based biotechnology start-up Anchor Therapeutics has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, a unit of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
